European Journal of Cancer Vol. 30A, No. 5, p. 723, 1994.

0959-8049/94 $7.00 + 0.00

0959-8049(94)E0085-5

Dose Intensification in the Treatment of Patients With Testicular Germ Cell Tumours

S.M. O'Reilly, D. B. Smith, E. S. Newlands and G. J. S. Rustin

IN A RECENT edition of the *European Journal of Cancer*, Abrizzoni and colleagues reported the results of a study aimed at determining the feasibility of using granulocyte–macrophage colony stimulating factor (GM-CSF) to facilitate delivery of high dose intensity chemotherapy to patients with small cell lung cancer [1]. Their results demonstrate that, although the use of GM-CSF did allow some increase in delivered dose intensity, cumulative haematological toxicity (particularly thrombocytopenia) precluded the administration of more than a limited number of courses. Moreover, toxicities other than myelosuppression have also been reported to become dose limiting using this approach to dose intensification [2].

A recent review of the literature has supported the concept of dose intensification in the treatment of patients with testicular germ cell tumours [3]. We devised a high dose intensity weekly chemotherapy schedule comprising bleomycin 15 mg intramuscular (i.m.), etoposide 100 mg/m^2 intravenous (i.v.), vincristine 1.0 mg/m^2 i.v. (maximum 2 mg) and cisplatin 75 mg/m^2 i.v. (BEOP) for patients with resistant or relapsed germ cell tumours. In an initial cohort of 13 patients, treatment was given weekly provided that the white blood cell count (WBC) was $\geq 2.0 \times 10^9$/l and the platelet count was $\geq 50 \times 10^9$/l. If myelosuppression occurred, treatment was delayed until blood counts had recovered to these levels. Cisplatin dose was reduced if significant deterioration in renal function occurred. In a pilot study, all 9 patients who received four or more cycles of BEOP experienced treatment delays and/or dose reductions. There were a total of 14 delays in treatment either due to neutropenia ± thrombocytopenia ($n = 11$) or thrombocytopenia alone ($n = 3$). In addition, cisplatin dose was reduced in 40 (48%) courses. Having defined the toxicity of BEOP without colony stimulating factor support, we then treated a second cohort of patients using filgrastim (G-CSF), kindly supplied by Amgen, in conjunction with BEOP. Patients received weekly BEOP until the WBC was $<2.0 \times 10^9$/l. Treatment was then delayed until haematological recovery and patients subsequently received filgrastim 5 μg/kg subcutaneous daily for 5 days between cycles of BEOP.

17 patients entered this part of the study. 2 patients were withdrawn from study during weeks 1–4 due to renal failure and 1 patient died from an infection after course 3. The remaining 14 patients received a total of 115 cycles of BEOP. The median time to first treatment delay was 4 weeks (range 3–5) and this delay was due to neutropenia ± thrombocytopenia in 13/14 patients. Following haematological recovery, treatment with filgrastim was initiated between cycles of therapy. 4 patients did not experience further dose delays. However, the remaining 10 patients experienced 15 further dose delays: three delays were due to neutropenia alone, four to neutropenia and thrombocytopenia, six to thrombocytopenia alone and two to non-neutropenic sepsis. In addition, a reduction in cisplatin dose because of significant deterioration in renal function (i.e. glomerular filtration rate failing to <50 ml/min) was necessary in 33/115 (29%) courses. Thus, while filgrastim support allowed BEOP chemotherapy to be delivered with fewer treatment delays due to neutropenia, thrombocytopenia and nephrotoxicity continued to be major problems limiting the intensity of chemotherapy possible with this schedule. Although the use of currently available CSFs may abrogate chemotherapy-induced neutropenia, alternative toxicities (both haematological and non-haematological) may still preclude significant dose intensification.

1. Ardizzoni A, Venturi M, Crino L, *et al.* High dose-intensity chemotherapy with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte–macrophage colony-stimulating factor in the treatment of small cell lung cancer. *Eur J Cancer* 1993, **29A**, 687–692.
2. Bronchud MH, Howell A, Crowther D, *et al.* The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. *Br J Cancer* 1989, **60**, 121–125.
3. Broun ER, Nichols CR. High dose chemotherapy in the management of germ cell tumours. In Armitage JO, Antman K, eds. *High-dose Cancer Therapy: Pharmacology, Haematopoeitins, Stem Cells.* Baltimore, Williams & Wilkins, 1992, 690–700.

Correspondence to S. M. O'Reilly.
The authors are at the CRC Laboratories, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, U.K.
Received 7 Oct. 1993; accepted 11 Oct. 1993.

European Journal of Cancer Vol. 30A, No. 5, pp. 723–724, 1994.

0959-8049/94 $7.00 + 0.00

0959-8049(93)E0103-W

The Concomitant Expression of Oncogenes and Growth Factors in Human Breast Cancer

R. Spaventi, K. Pavelic, Z.P. Pavelic and J.L. Gluckman

TUMORIGENESIS HAS long been thought to be a multistep process [1]. Evidence from experiments with primary rodent cells, and also from studies on transgenic animals, indicate that the

Correspondence to R. Spaventi.
R. Spaventi and K. Pavelic are at the Department of Molecular Medicine, Rugjer Boskovic Institute, Zagreb, Croatia; and Z.P. Pavelic and J.L. Gluckman are at the Department of Otolaryngology-Head and Neck Surgery, College of Medicine University of Cincinnati, Cincinnati, Ohio, U.S.A.
Received 4 Nov. 1993; accepted 11 Nov. 1993.